Global Biologics Market – Industry Trends and Forecast to 2029

Market Analysis and Size                              

Biologics have acquired a lot of momentum in recent years since they are used to treat a variety of diseases and ailments, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, and other autoimmune diseases. The product's widespread use is expected to drive growth in the global biologics market in the coming years. Biologics are at the cutting edge of research, supporting the most recent advances. Such breakthroughs are expected to result in revolutionary treatments that give patients new treatment options. New developments and unique therapies are being developed for the production of new biologics, indicating that the global biologics market is anticipated to have a positive future outlook.

Data Bridge Market Research analyses that the biologics market was valued at USD 264 billion in 2021 and is expected to reach USD 596.65 billion by 2029, registering a CAGR of 9.25% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Biologics, commonly referred to as biological medications, are disease-modifying antirheumatic drugs (DMARDs) that are manufactured from live creatures or contain living organism components. Vaccines, blood, blood components, tissues, cells, allergies, genes, and recombinant proteins are among the items derived from humans, insects, microbes, animals, plants, and birds. These products regulate the development of essential proteins, alter human hormones and cells, and produce compounds that either activate or suppress the immune system. They also alter the way natural biologic intracellular and cellular activities function.

Biologics Market Dynamics

Drivers

• Rise in the prevalence of chronic diseases

The surging prevalence of chronic diseases is a major factor driving the biologics market's growth rate during the forecast period of 2022-2029. As per World Health Organization (WHO), chronic diseases kill more than 41 million people worldwide each year. The most common chronic disease, cardiovascular disease, kills 17.9 million people per year, followed by cancer, diabetes and respiratory disorders. These four groups are responsible for 80% of all chronic disease mortality. Chronic diseases have prompted the development of sophisticated diagnostics and therapeutics. Biologics are medicines that have been genetically modified to target a portion of the immune system that causes inflammation.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of biologics market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the biologics market. Additionally, sedentary lifestyle of people and surging geriatric population will result in the expansion of biologics market. Along with this, favourable reimbursement policies will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the biologics market growth. In addition, scientists and researchers are studying species and expression systems to improve biological products' productivity. In addition, a number of pharmaceutical companies are conducting research and development (R and D) to increase the efficacy of oral medications for rheumatoid arthritis and Crohn's disease. Along with this, rising drug approvals and launches will further propel the market's growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the biologics market during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the biologics market. Additionally, lack of awareness about the utilization of biologics in research centers will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029. Biologics are sensitive to heat and light, due to which they require a superior refrigeration procedure that is not consistent over the world. This is estimated to obstruct the market's growth rate. .

This biologics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biologics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Biologics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Biologics Market

The COVID-19 outbreak and subsequent lockdown in numerous countries around the world had a huge impact on the financial status of enterprises in all sectors. The private healthcare sector is one of the areas where the pandemic had a significant impact. The coronavirus pandemic had a significant influence on medicine development, production, supply, and the businesses of different healthcare corporations around the world. The outbreak has resulted in the shutdown of industrial establishments, with the exception of those that manufacture critical commodities, and disruptions in product supply chains. As a result, the COVID-19 outbreak had impacted the economy in three ways: directly influencing production and demand, causing distribution channel disruptions, and having a financial impact on firms and financial markets.

On the brighter side, during the pandemic, there was a high need for biologics due to the increased COVID-19 burden, which further fuelled the market's growth rate. The National Research Council of Canada and CanSino Biologics, located in China, partnered in May 2020 to develop a COVID-19 vaccine for clinical use in Canada. Ad5-nCoV is an adenovirus Type 5 vector-based vaccination that is currently being developed in Wuhan, China. As a result, the COVID-19 outbreak had a positive impacted on the biologics market. Furthermore, the number of research and development activities on biologics for the treatment of COVID-19 is also increased. Additionally, the governments of various countries are also taking new initiatives for promoting the healthcare sector and ensuring the availability of biologics

Recent Development

• In November 2021, Bristol-Myers Squibb Company had received the U.S. Food and Drug Administration approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer. Patients with squamous or non-squamous illness, independent of PD-L1 expression, are eligible for the treatment. 1 The FDA's Real-Time Oncology Examine (RTOR) pilot programme was used to review this application, which aims to ensure that safe and effective medicines are offered to patients as soon as feasible.

Global Biologics Market Scope

The biologics market is segmented on the basis of type, drug class, therapeutic application, source, manufacturing, drug type, mode of purchase, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Tumor Necrosis Factor (TNF) Inhibitor
• T-cell Inhibitor
• Selective Co-stimulation Modulators
• Interleukin-6 (IL-6) or Interleukin-17 Blocker
• Interleukin-1 (IL-1) Blocker
• B-cell Inhibitor

Drug Class

• Monoclonal Antibody
• Recombinant Insulin
• Vaccine
• Blood Factor
• Human Growth Hormone
• Erythropoietin
• Fusion Protein
• Recombinant Enzyme
• Interferon
• Colony-stimulating Factor
• Gene Therapy
• Cell Therapy
• Oligonucleotides
• Others
• Peptide
• Botulinum Toxin
• Others

Therapeutic Application

• Oncology
• Autoimmune/Immunologic Diseases
• Metabolic Disorders
• Ophthalmic Diseases
• Respiratory Disorders
• Inflammatory Bowel Diseases (IBDs)
• Neurological Disorders
• Cardiovascular Diseases (CVDs)
• Musculoskeletal Disorders (MSDs)
• Infectious Diseases
• Others

Source

• Microbial
• Mammalian
• Others

Manufacturing

• Outsourced
• In-House

Drug Type

• Branded Drugs
• Generic Drugs

Mode of Purchase

• Prescription Drugs
• Over-The-Counter (OTC) Drugs

Dosage Form

• Injection
• Tablets
• Others

Route of Administration

• Parenteral
• Oral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Biologics Market Regional Analysis/Insights

The biologics market is analysed and market size insights and trends are provided by country, drug type, drug class, therapeutic application, source, manufacturing, drug type, mode of purchase, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the biologics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the biologics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, increase in strategic collaborations for the development of biologics treatment for acute as well as chronic diseases will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to surging prevalence of rheumatoid arthritis, kidney and liver disorders in this region. Also, development of healthcare infrastructure and rising geriatric population will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Biologics Market Share Analysis

The biologics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to biologics market.

Some of the major players operating in the biologics market are:

• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Merck & Co., Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (US)
• Eli Lilly and Company (US)
• Allergan (Ireland)
• Abbott (US)
• LEO Pharma A/S (Denmark)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (UK)
• Zydus Cadila (India)

SKU-56794